| |
| |
|
| Insider
Information: |
Meglasson Martin |
| Relationship: |
Chief Scientific Officer |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
121,348 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,308,018 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
121,348 |
|
|
| Total
Value |
$7,308,018 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
V-P, Discovery Research |
2010-05-11 |
102,250 |
2004-11-11 |
0 |
Premium* |
|
|
Bellerophon Therapeutics Inc |
BLPH |
Chief Scientific Officer |
2015-05-20 |
19,098 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BLPH |
Bellerophon Therapeutics ... |
Chief Scientific Officer |
• – – |
2015-05-20 |
4 |
B |
$8.40 |
$5,981 |
D/D |
712 |
19,098 |
2.74 |
- |
|
| BLPH |
Bellerophon Therapeutics ... |
Chief Scientific Officer |
• – – |
2015-02-19 |
4 |
B |
$12.00 |
$144,000 |
D/D |
12,000 |
18,386 |
2.74 |
- |
|
| BLPH |
Bellerophon Therapeutics ... |
Chief Scientific OfficerOffice |
• – – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,991 |
|
- |
|
| BLPH |
Bellerophon Therapeutics ... |
Chief Scientific OfficerOffice |
• – – |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,395 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2010-05-11 |
4 |
B |
$1.63 |
$10,188 |
D/D |
6,250 |
102,250 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2010-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
96,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2009-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
67,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2009-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
76,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2008-05-09 |
4 |
B |
$3.36 |
$10,077 |
D/D |
3,000 |
36,500 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2008-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
33,500 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2008-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
44,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2007-08-30 |
4 |
B |
$6.19 |
$12,386 |
D/D |
2,000 |
13,500 |
2.74 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2007-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
11,500 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2006-12-15 |
4 |
S |
$11.23 |
$59,656 |
D/D |
(5,313) |
500 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2006-12-15 |
4 |
OE |
$7.25 |
$38,519 |
D/D |
5,313 |
5,813 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
V-P, Discovery Research |
• – – |
2004-11-11 |
4 |
B |
$8.82 |
$4,410 |
D/D |
500 |
500 |
2.66 |
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
